BostonGene and Daiichi Sankyo are collaborating to integrate artificial intelligence (AI)-driven translational intelligence into an antibody-drug conjugate (ADC) development program.

The aim of the ADC program, developed by Daiichi Sankyo, is to move beyond standard exploratory biomarker analysis. To do this, the program promises to deliver decision-ready insights to directly inform patient selection strategies.

It will also assist in development prioritization and translational positioning, leveraging BostonGene’s AI foundation model for tumor and immune biology.

How BostonGene AI Platform Works

How that model works is by generating digital twin representations from hundreds of thousands of multiomic and histopathologic patient profiles. With this, BostonGene is able to identify exact biological signatures and efficacy-associated mechanisms.

In short, these signposts differentiate responders from non-responders.

In the collaboration with Daiichi Sankyo, BostonGene’s deep molecular mapping will serve to define unique molecular subgroups. BostonGene’s platform will benchmark investigational medicines relative to existing approved treatments and standards of care.

BostonGene Chief Medical Officer Nathan Fowler, MD, said success in modern drug development is no longer defined by data volume.

Rather, Fowler said, it is “the speed and accuracy with which we translate biological complexity into clinical outcomes.”

“Our work with Daiichi Sankyo is focused on accelerating learning cycles [and] lowering the cost of uncertainty,” Fowler said.

Role of Daiichi Sankyo in Partnership

By differentiating this medicine earlier, Fowler continued, the partnership will identify the most likely benefits to patients with cancer.

BostonGene said analyses produced by this collaboration will enable clear asset differentiation, identifying both unique therapeutic profiles and biological advantages.

Also, insights into resistance pathways the platform provides will inform the tumor microenvironment necessary for future trial and clinical design.

This adds to a busy 2026 so far for Daiichi Sankyo. The company opened headquarters in Toronto, invested $1.9 billion in manufacturing facilities, and signed a licensing agreement with GENESIS Pharma.